Search details
1.
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
N Engl J Med
; 2024 Jun 07.
Article
in English
| MEDLINE | ID: mdl-38847460
2.
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
N Engl J Med
; 390(9): 795-805, 2024 Feb 29.
Article
in English
| MEDLINE | ID: mdl-37962077
3.
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
N Engl J Med
; 390(6): 497-509, 2024 02 08.
Article
in English
| MEDLINE | ID: mdl-38324483
4.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Nature
; 592(7854): 450-456, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33762733
5.
A global action agenda for turning the tide on fatty liver disease.
Hepatology
; 79(2): 502-523, 2024 Feb 01.
Article
in English
| MEDLINE | ID: mdl-37540183
6.
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
Gut
; 73(5): 825-834, 2024 Apr 05.
Article
in English
| MEDLINE | ID: mdl-38199805
7.
Inequities in primary liver cancer in Europe: The state of play.
J Hepatol
; 80(4): 645-660, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38237866
8.
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
J Hepatol
; 80(3): 419-430, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37984709
9.
Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
Lancet
; 402(10406): 988-996, 2023 09 16.
Article
in English
| MEDLINE | ID: mdl-37572680
10.
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
N Engl J Med
; 385(17): 1547-1558, 2021 10 21.
Article
in English
| MEDLINE | ID: mdl-34670042
11.
Accuracy, Reliability, and Comprehensibility of ChatGPT-Generated Medical Responses for Patients With Nonalcoholic Fatty Liver Disease.
Clin Gastroenterol Hepatol
; 22(4): 886-889.e5, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-37716618
12.
Spleen Stiffness-Based Algorithms Are Superior to Baveno VI Criteria to Rule Out Varices Needing Treatment in Patients With Advanced Chronic Liver Disease.
Am J Gastroenterol
; 2024 Mar 20.
Article
in English
| MEDLINE | ID: mdl-38502095
13.
The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories.
Hepatology
; 78(3): 911-928, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-37595128
14.
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study.
Hepatology
; 78(4): 1223-1239, 2023 10 01.
Article
in English
| MEDLINE | ID: mdl-37162151
15.
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.
Hepatology
; 78(1): 258-271, 2023 07 01.
Article
in English
| MEDLINE | ID: mdl-36994719
16.
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
Hepatology
; 78(1): 195-211, 2023 07 01.
Article
in English
| MEDLINE | ID: mdl-36924031
17.
Liver stiffness as a cornerstone in heart disease risk assessment.
Liver Int
; 44(2): 344-356, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38014628
18.
The sclerotic component of metabolic syndrome: Fibroblast activities may be the central common denominator driving organ function loss and death.
Diabetes Obes Metab
; 26(7): 2554-2566, 2024 Jul.
Article
in English
| MEDLINE | ID: mdl-38699780
19.
A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials.
J Hepatol
; 79(3): 829-841, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37001695
20.
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
J Hepatol
; 78(1): 57-66, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36031158